Lupin Limited

Lupin Limited (Mumbai, India). 2024 revenue ~$2.6B. Complex generics: inhalation, injectable. APIs: 80+ markets. Strong in TB, cardiovascular, diabetes. 3rd largest US generic RX by volume.